ADVANCED ENZYME TECHNOLOGIES | ZENOTECH LABS | ADVANCED ENZYME TECHNOLOGIES/ ZENOTECH LABS |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 29.1 | 68.3 | 42.7% | View Chart |
P/BV | x | 3.1 | 5.0 | 61.8% | View Chart |
Dividend Yield | % | 1.4 | 0.0 | - |
ADVANCED ENZYME TECHNOLOGIES ZENOTECH LABS |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ADVANCED ENZYME TECHNOLOGIES Mar-24 |
ZENOTECH LABS Mar-24 |
ADVANCED ENZYME TECHNOLOGIES/ ZENOTECH LABS |
5-Yr Chart Click to enlarge
|
||
High | Rs | 425 | 81 | 524.8% | |
Low | Rs | 233 | 47 | 501.0% | |
Sales per share (Unadj.) | Rs | 55.8 | 6.7 | 833.9% | |
Earnings per share (Unadj.) | Rs | 12.2 | 1.4 | 900.7% | |
Cash flow per share (Unadj.) | Rs | 15.4 | 2.5 | 610.9% | |
Dividends per share (Unadj.) | Rs | 5.10 | 0 | - | |
Avg Dividend yield | % | 1.6 | 0 | - | |
Book value per share (Unadj.) | Rs | 118.1 | 14.8 | 796.4% | |
Shares outstanding (eoy) | m | 111.82 | 61.03 | 183.2% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 5.9 | 9.5 | 61.9% | |
Avg P/E ratio | x | 26.9 | 46.9 | 57.3% | |
P/CF ratio (eoy) | x | 21.4 | 25.3 | 84.5% | |
Price / Book Value ratio | x | 2.8 | 4.3 | 64.8% | |
Dividend payout | % | 41.6 | 0 | - | |
Avg Mkt Cap | Rs m | 36,793 | 3,891 | 945.7% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 1,284 | 95 | 1,356.4% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 6,239 | 408 | 1,527.9% | |
Other income | Rs m | 370 | 10 | 3,682.7% | |
Total revenues | Rs m | 6,608 | 418 | 1,579.6% | |
Gross profit | Rs m | 1,902 | 172 | 1,104.4% | |
Depreciation | Rs m | 352 | 71 | 497.4% | |
Interest | Rs m | 41 | 0 | - | |
Profit before tax | Rs m | 1,878 | 111 | 1,685.9% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 509 | 28 | 1,789.3% | |
Profit after tax | Rs m | 1,370 | 83 | 1,650.2% | |
Gross profit margin | % | 30.5 | 42.2 | 72.3% | |
Effective tax rate | % | 27.1 | 25.5 | 106.1% | |
Net profit margin | % | 22.0 | 20.3 | 108.0% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 8,097 | 262 | 3,095.0% | |
Current liabilities | Rs m | 1,064 | 135 | 786.5% | |
Net working cap to sales | % | 112.7 | 31.0 | 364.2% | |
Current ratio | x | 7.6 | 1.9 | 393.5% | |
Inventory Days | Days | 248 | 53 | 463.5% | |
Debtors Days | Days | 58 | 29,046 | 0.2% | |
Net fixed assets | Rs m | 7,114 | 735 | 967.7% | |
Share capital | Rs m | 224 | 610 | 36.6% | |
"Free" reserves | Rs m | 12,987 | 295 | 4,400.8% | |
Net worth | Rs m | 13,211 | 905 | 1,459.1% | |
Long term debt | Rs m | 70 | 0 | - | |
Total assets | Rs m | 15,212 | 997 | 1,526.1% | |
Interest coverage | x | 46.6 | 0 | - | |
Debt to equity ratio | x | 0 | 0 | - | |
Sales to assets ratio | x | 0.4 | 0.4 | 100.1% | |
Return on assets | % | 9.3 | 8.3 | 111.4% | |
Return on equity | % | 10.4 | 9.2 | 113.1% | |
Return on capital | % | 14.5 | 12.3 | 117.5% | |
Exports to sales | % | 17.6 | 0 | - | |
Imports to sales | % | 9.5 | 0 | - | |
Exports (fob) | Rs m | 1,097 | NA | - | |
Imports (cif) | Rs m | 594 | NA | - | |
Fx inflow | Rs m | 1,097 | 0 | - | |
Fx outflow | Rs m | 594 | 0 | - | |
Net fx | Rs m | 502 | 0 | - |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 1,414 | 118 | 1,195.7% | |
From Investments | Rs m | -646 | -212 | 305.6% | |
From Financial Activity | Rs m | -592 | NA | - | |
Net Cashflow | Rs m | 173 | -93 | -185.8% |
Indian Promoters | % | 2.0 | 68.8 | 2.9% | |
Foreign collaborators | % | 41.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 20.7 | 1.0 | 2,085.9% | |
FIIs | % | 12.6 | 0.0 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 57.1 | 31.2 | 183.1% | |
Shareholders | 66,758 | 10,641 | 627.4% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare ADVANCED ENZYME TECHNOLOGIES With: DIVIS LABORATORIES CIPLA SUN PHARMA DR. REDDYS LAB MANKIND PHARMA
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | ADVANCED ENZYME TECHNOLOGIES | ZENOTECH LABS | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | -0.08% | -2.69% | 0.97% |
1-Month | -16.08% | -0.69% | 1.29% |
1-Year | 10.18% | 10.86% | 46.30% |
3-Year CAGR | 3.06% | 18.39% | 19.65% |
5-Year CAGR | 16.72% | 22.37% | 26.13% |
* Compound Annual Growth Rate
Here are more details on the ADVANCED ENZYME TECHNOLOGIES share price and the ZENOTECH LABS share price.
Moving on to shareholding structures...
The promoters of ADVANCED ENZYME TECHNOLOGIES hold a 43.0% stake in the company. In case of ZENOTECH LABS the stake stands at 68.8%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of ADVANCED ENZYME TECHNOLOGIES and the shareholding pattern of ZENOTECH LABS.
Finally, a word on dividends...
In the most recent financial year, ADVANCED ENZYME TECHNOLOGIES paid a dividend of Rs 5.1 per share. This amounted to a Dividend Payout ratio of 41.6%.
ZENOTECH LABS paid Rs 0.0, and its dividend payout ratio stood at 0.0%.
You may visit here to review the dividend history of ADVANCED ENZYME TECHNOLOGIES, and the dividend history of ZENOTECH LABS.
For a sector overview, read our pharmaceuticals sector report.
Asian stocks experienced a notable rally alongside US equity futures on Monday, marking a positive turn for the markets. The dollar retreated against other currencies as bond yields declined.